Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 1/20 | 0.56 |
| ▸ | PDE2A | O00408 | 4/20 | 0.54 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.41 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 8/20 | 0.39 |
| ▸ | CDC25B | P30305 | 8/20 | 0.39 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.39 |
| ▸ | PTPN6 | P29350 | 3/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 3/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11420439 | 0.84 | PDE2A (0.61) | HTR1APDE2ABCHETP53MDM2 | |
| SCHEMBL750344 | 0.83 | PDE2A (0.72) | HTR1APDE2ABCHE | |
| SCHEMBL9097705 | 0.78 | PDE2A (0.70) | HTR1APDE2ABCHETP53 | |
| SCHEMBL8764444 | 0.78 | PDE2A (0.70) | HTR1APDE2ABCHE | |
| SCHEMBL11227449 | 0.77 | HTR1A (0.55) | HTR1APDE2ABCHETP53MDM2 | |
| SCHEMBL5961364 | 0.77 | PDE2A (0.64) | HTR1APDE2ABCHE | |
| SCHEMBL11427985 | 0.77 | PDE2A (0.64) | HTR1APDE2ABCHE | |
| SCHEMBL6306351 | 0.76 | PDE2A (0.61) | HTR1APDE2ABCHETP53MDM2 | |
| SCHEMBL6306348 | 0.76 | PDE2A (0.61) | HTR1APDE2ABCHETP53MDM2 | |
| SCHEMBL19100925 | 0.74 | PDE2A (0.60) | PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6884880-B2 | Process for the preparation of 9-β-anomeric nucleoside analogs | ASH STEVENS, INC. (US) | 2005-04-26 | — | — | US | disclosed |
| US-20040039190-A1 | Process for the preparation of 9-beta-anomeric nucleoside analogs | ASH STEVENS, INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039190-A1 | Process for the preparation of 9-beta-anomeric nucleoside analogs | DPYD, SLC29A2, GALE | HTR1A 2282/4885PDE2A 1120/4885BCHE 2476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.